Business ❯ Pharmaceuticals ❯ Drug Development

Clinical Trials

Weight Loss Drugs Obesity Treatments FDA Approval Regulatory Approval Market Impact Cancer Treatments Phase 3 Trials Moderna RNA-based Therapies Bexobrutideg

Novartis Faces Investor Backlash After Second Late‑Stage Trial Failure

The company is reviewing full del‑desiran data to guide regulator talks with remibrutinib's October readouts serving as the next major test.

Novartis’ Del‑Desiran Misses Phase III and Triggers Large Share Selloff

Novartis' Pelacarsen Fails Phase 3 After Lowering Lp(a)

Ultragenyx Phase 3 Angelman Drug Fails to Show Benefit

FDA Approves First Broad RAS Inhibitor for Metastatic Pancreatic Cancer

BioMarin to Buy Alesta for $275 Million to Add Oral HPP Drug

GSK to Close Stevenage Hub and Build £400m Cambridge R&D Centre

AstraZeneca Licenses Global Rights to Zegfrovy From Dizal

Definium’s Oral LSD Pill Meets Primary Endpoint in Phase 3 Depression Trial

Roche and Nurix Strike $700M Deal to Co‑Develop Oral BTK Degrader Bexobrutideg

Zealand Pharma Shares Tumble After Survodutide Phase III Shows High Dropouts

Lilly Secures Global Rights to Hanmi’s Sonefpeglutide

Vertex’s IgA Nephropathy Drug Hits Phase 3 Goals, FDA Filing Slated for March

Novo Nordisk Plunges After Obesity Drug Cagrisema Misses Phase-3 Goal

Lilly’s Taltz Plus Zepbound Outperforms Taltz Alone in Phase 3b Psoriasis-Obesity Trial

Compass Pathways’ Psilocybin Therapy Hits Phase 3 Goal in Treatment-Resistant Depression

Bayer’s Asundexian Cuts Recurrent Stroke by 26% in Phase III Without Added Major Bleeding

GSK and Ionis Report Phase 3 Success for Hepatitis B Drug, Plan Q1 Filings

Genmab Halts Acasunlimab to Focus on Late-Stage Cancer Portfolio

Cosmo’s Clascoterone Meets Phase III Goals in Male-Pattern Baldness Trials